Cyvex’ Chirositol™ study “Synergistic Effects of D-Chiro-Inositol and Manganese on Blood Glucose and Body Weight of Streptozotocin-Induced Diabetic Rats” has been published in the international peer review journal Current Bioactive Compounds.

The purpose of the study was to investigate the efficacy of prolonged oral administration of Chirositol™ >95% D-Chiro-Inositol (DCI) alone and in combination with manganese sulfate on reducing blood glucose in streptozotocin (STZ)-induced diabetic rats.  The known benefits of DCI have been suggested in sugar metabolism, polycystic ovarian syndrome (PCOS), and weight loss.

In the study, Chirositol™ and manganese sulfate were administered orally, singly, and in combination to diabetic-induced rats for 21 days.  Oral Chirositol™ administration to diabetic rats for 12 days decreased their blood glucose by 23% as compared to controls.  Oral Chirositol™   and manganese sulfate administration to diabetic rats for 12 days decreased their blood glucose by 40% as compared to controls.  Experimental groups did not display hypoglycemia either clinically or by blood glucose levels and/or demonstrated any other adverse reactions.  Of further interest, body weights of both female and male rats administered Chirositol™ and manganese sulfate were reduced, with females 25% compared to controls and males 21% compared to controls over the 21-day period.

With over 30 plus published scientific studies in peer review journals since 1979 providing insight in metabolic disorders, mechanism of action, and established safety, Chirositol™ and Chirositol™ M (containing manganese sulfate) contribute their role in the overall understanding of diabetes mellitus.

For more information on Chirositol™ visit www.chirositol.com or if you would like to view the study, please contact sales@cyvex.com

A randomized study involving 25 women with PCOS (mean age 32.7 yr.; mean body mass index 34.8m²) showed that 4 g/day omega-3 fatty acid supplementation for 8 weeks significantly decreased liver fat content, fasting lipids, and systolic and diastolic blood pressure. Marine-derived omega-3 fatty acids particularly decreased hepatic fat in women with hepatic steatosis, defined as liver fat percentage greater than 5%.

These results are encouraging for very obese women with PCOS. Previous studies had shown that mild reduction in excess body weight (5-10%) positively affected the response of very obese women to supplementation of D-chiro-inositol .  Research had shown that very obese subjects simply excrete inositol, preventing therapeutic levels from being achieved in the blood and tissue. Therefore, supplementation of D-chiro-inositol in combination with marine-derived omega-3 fatty acids will effectively increase chances of treating PCOS in very obese women improving their metabolic parameters and fertility.

References:

1. Cussons AJ, et al. Omega-3 fatty acids supplementation decreases liver fat content in Polycyctic Ovary Syndrome: A randomized controlled trial employing Proton Magnetic Resonance Spectroscopy. J Clin Endocrinol Metab. 2009; 94: 3842–3848.
2. Kiddy DS, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with Polycystic Ovary Syndrome. Clin Endocrinol. 1992. 36: 105-111
3. Huber-Buchholz MM, DG Carey, RJ Norman. Restoration of reproductive potential by lifestyle modification in obese Polycyctic Ovary Syndrome: role of insulin sensitivity and luteinizing hormone. 1999; J. Clin. Endocrinol. Metab. 84: 1470-1474
4. Moran L, RJ Norman. Understanding and managing disturbances in insulin metabolism and body weight in women with Polycyctic Ovary Syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 2004; 18: 719-736

*Note: Please email us at sales@cyvex.com or use the Contact Us form for more information